Specialised Therapeutics Asia will partner with CTTQ-Akeso to commercialise a new immuno-oncology therapy in Australia, Singapore and across Southeast Asia.
- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
Press Releases - Specialised Therapeutics - Page 2
April 12, 2023
February 17, 2023
Global Sarcoma Therapy Now Approved for New Zealand Patients
Singapore and Auckland, New Zealand, 17 February 2023: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue sarcomas has now been approved in New Zealand.
January 20, 2023
New Therapy to Treat Rare Gastrointestinal Stromal Tumour Approved for New Zealand Patients
Singapore and New Zealand, 20 January 2023: Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now been approved in New Zealand.
September 16, 2022
New Treatment for Rare Cancer Cholangiocarcinoma Approved in Australia
Melbourne, Australia 15 September 2022: A NEW targeted therapy to treat a rare bile duct cancer called cholangiocarcinoma has been approved for use in Australia.
July 13, 2022
New Therapy for Rare Gastrointestinal Stromal Tumours Accepted in Singapore for Regulatory Evaluation
Singapore, 12 July 2022: A novel therapy to treat rare gastrointestinal stromal tumours (GIST) has been accepted for evaluation by Singapore’s Health Sciences Authority.
July 8, 2022
New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in the Philippines
Singapore, 8 July 2022: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer is now approved by the Food and Drug Administration of the Philippines. The drug, NERLYNX (neratinib) is an oral medication taken daily for 12 months by women who have been diagnosed with early-stage HER2-positive (HER2+) breast cancer and who have received prior trastuzumab-based therapy.
July 5, 2022
Specialised Therapeutics Appoints New Logistics Partner
Singapore, 4 July 2022: International biopharmaceutical company Specialised Therapeutics (ST) has struck an important agreement with highly recognised logistics partner Healthcare Logistics (HCL) to store and distribute its growing portfolio of specialist healthcare products in Australia.
March 29, 2022
New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in Malaysia
Singapore, 29 March 2022: A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer is now available in Malaysia. The drug, NERLYNX® (neratinib) is an oral medication taken for 12 months by women who have been diagnosed with early stage HER2-positive (HER2+) breast cancer and who have received prior trastuzumab-based therapy.
November 15, 2021
‘Great Relief’ for Australian Patients with New Therapy to Treat Rare GIST Cancers Listed on PBS
QINLOCK® (ripretinib) now PBS listed for Australian patients QINLOCK is the first new reimbursed therapy to treat advanced GIST in more than a decade Leading Australian oncologist says the listing will help to “buy patients more time” Data shows QINLOCK reduces risk of disease progression by 85%1, 2 14 November, 2021: AUSTRALIAN cancer patients
October 22, 2021
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies
Singapore, 22 October 2021: Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios, tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®). Under the